Abstract
Background: The tubulin depolymerising drug Combretastatin A-1 phosphate (CA1P), a water-soluble derivative of combretastatin A-1, has been recently shown to have a better efficacy in experimental models than the clinically active, close structural analogue, combretastatin A-4 phosphate (CA4P). Previous studies with CA4P in combination with standard anti-cancer agents have demonstrated improved efficacy relative to the standard agents. Materials and Methods: In this study the synergistic effects of administering CA1P in combination with cisplatin (CPL) in a well-differentiated transplantable murine colon model (MAC 29) was evaluated. Results: CA1P at 100mgkg-1 significantly potentiated the anti-tumour effects of CPL. The effect with CPL was similar to that seen for CA1P at its maximum tolerated dose (MTD) alone. Conclusion: These data demonstrate that the combination of CA1P and CPL has significant preclinical antitumour activity against a transplantable murine adenocarcinoma model that is related to the antivascular effects of CA1P.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1619-1623 |
| Number of pages | 5 |
| Journal | Anticancer Research |
| Volume | 23 |
| Issue number | 2 B |
| State | Published - Mar 2003 |
Keywords
- Anti-vascular effects
- Combination chemotherapy
- Combretastatins
- MAC murine tumour model
ASJC Scopus subject areas
- Oncology
- Cancer Research